What is the recommended dose titration for Aricept (donepezil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Donepezil (Aricept) Dose Titration Protocol

The recommended dose titration for donepezil (Aricept) begins with 5 mg once daily in the evening for 4-6 weeks, then increasing to 10 mg once daily if well tolerated, with a potential increase to 23 mg daily after at least 3 months on 10 mg for patients with moderate to severe Alzheimer's disease. 1

Initial Dosing and Titration Schedule

Mild to Moderate Alzheimer's Disease

  • Starting dose: 5 mg once daily in the evening, just prior to retiring
  • Titration: After 4-6 weeks on 5 mg daily, may increase to 10 mg daily if well tolerated
  • Maximum dose: 10 mg once daily 1

Moderate to Severe Alzheimer's Disease

  • Starting dose: Same as above (5 mg once daily)
  • First titration: After 4-6 weeks on 5 mg daily, may increase to 10 mg daily
  • Second titration: After at least 3 months on 10 mg daily, may increase to 23 mg daily
  • Maximum dose: 23 mg once daily 1

Administration Guidelines

  • Take in the evening, just prior to retiring
  • Can be taken with or without food
  • The 5 mg and 10 mg tablets can be split if needed
  • The 23 mg tablet should NOT be split, crushed, or chewed 1

Monitoring and Dose Adjustments

Efficacy Assessment

  • Evaluate beneficial response after 6-12 months of treatment 2
  • Consider discontinuation if:
    • Side effects develop and don't resolve
    • Continued deterioration at pre-treatment rate after 6-12 months

Special Populations

  • Hepatic impairment:
    • No dose adjustment needed for mild to moderate hepatic disease
    • More caution and potentially lower dosing for severe hepatic impairment
    • Donepezil has no significant hepatotoxicity, unlike some other cholinesterase inhibitors 2, 3
  • Renal impairment: No specific dose adjustments required in the FDA labeling

Side Effect Management

Common Side Effects

  • Gastrointestinal: nausea, vomiting, diarrhea (more common with 10 mg than 5 mg, and more common with 23 mg than 10 mg) 1
  • Neurological: dizziness, headache, insomnia 3

Minimizing Side Effects

  • The 6-week titration period (rather than faster titration) helps minimize cholinergic side effects 3
  • Taking the medication in the evening may reduce the impact of side effects
  • If side effects are problematic at 10 mg, consider returning to 5 mg dose

Clinical Pearls

  • Donepezil provides modest but significant benefits in cognitive function, with improvements of 1.9-2.9 points on the ADAS-Cog scale at 24 weeks compared to placebo 2
  • Benefits include improved cognition, global clinical function, activities of daily living, and behavioral symptoms 4
  • The long half-life (approximately 70 hours) allows for once-daily dosing 5
  • Unlike tacrine, donepezil does not require liver function monitoring as it has not shown evidence of hepatotoxicity 3

Common Pitfalls to Avoid

  • Titrating too quickly: Increasing the dose before the recommended 4-6 week period can lead to increased cholinergic side effects
  • Missing the opportunity for dose escalation: Some patients may benefit from the higher 10 mg dose but are never titrated up from 5 mg
  • Inappropriate use of 23 mg dose: The 23 mg dose should only be used after at least 3 months on 10 mg and only for moderate to severe Alzheimer's disease
  • Splitting the 23 mg tablet: This tablet has special formulation and should never be split, crushed, or chewed

Donepezil remains a first-line treatment for Alzheimer's disease with a well-established efficacy and safety profile when properly titrated according to this protocol.

References

Guideline

Treatment of Alzheimer's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Donepezil for dementia due to Alzheimer's disease.

The Cochrane database of systematic reviews, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.